APOA1 Allele-Specific CRISPR Knockout for Amyloidosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Dominant genetic disorders caused by mutations in the APOA1 gene, such as amyloidosis, are challenging to treat due to the need to selectively target and inactivate the mutant allele while preserving the functional allele.

Innovation Solution

Utilizing CRISPR technology with guide RNA molecules targeting heterozygous SNPs to specifically knock out the mutant APOA1 allele by introducing a double-strand break, while sparing the functional allele, thereby reducing the expression of the mutant protein and potentially treating amyloidosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If CRISPR technology is used to knock out the mutant allele, then the harmful protein aggregates are prevented, but there is a risk of affecting the functional allele

Engineering Contradiction:

Improveharmful protein aggregatesVSAvoidpreservation of functional allele

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The guide RNA is designed to recognize and bind specifically to the mutant allele sequence, creating a localized effect that disables only the harmful allele while leaving the functional allele intact. This allele-specific targeting resolves the contradiction by applying the CRISPR-Cas9 system's cutting action only where needed (at the mutant allele) rather than broadly affecting all copies of the gene.

Inventive Principle:

Principle #3Local quality

2Adaptability or versatility

If traditional gene therapy approaches are used, then both alleles may be affected, but it is difficult to achieve selective knockout of only the mutant allele

Engineering Contradiction:

Improveselective allele targetingVSAvoidgene therapy system

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The guide RNA acts as an intermediary molecule that mediates between the CRISPR-Cas9 system and the target DNA. By designing the guide RNA sequence to be complementary only to the mutant allele, it directs the Cas9 enzyme specifically to the harmful allele, enabling selective knockout without requiring complex targeting mechanisms or multiple components.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively inactivates the mutant APOA1 allele, preventing the formation of amyloid fibrils and ameliorating amyloidosis by allowing the expression of functional apoA-1 protein, thus offering a targeted therapeutic strategy for dominant genetic disorders.

Implementation Method 1

CRISPR technology with guide RNA molecules targeting heterozygous SNPs in the APOA1 gene to introduce double-strand breaks specifically in the mutant allele

Methodology Applied

Scientific EffectCRISPR nuclease cleavage:

Data Source

PatentUS20260110002A1Differential Knockout of An Allele of A Heterozygous Apolipoprotein A1 (APO1A) Gene

Publication Date: 2026.04.23 EMENDOBIO INC

AI summary

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID Nos: 1-1313 and compositions, methods, and uses thereof.